Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 14, 2005. The report serves to disclose specific changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) as required under the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting changes in equity holdings and does not contain financial performance data.
Material Changes
The filing details two specific transactions regarding directors' interests:
- Employee Share Option Plan: On June 13, 2005, the GlaxoSmithKline Employee Trust transferred 2,000 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J S Heslop are noted as having an interest in the trust.
- US Retirement Savings Plan: On June 9, 2005, the GlaxoSmithKline US Retirement Savings Plan experienced a movement in holdings, reducing the number of Ordinary Share ADRs from 18,318,099 to 18,305,200. The average price for this movement was $49.60. Directors Dr. J P Garnier and Dr. T Yamada are noted as having a potential interest in this fund.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses exclusively on regulatory disclosure of share ownership changes.
Key Facts for Investor Verification
- Verify the total number of shares held by the GSK Trust and the US Retirement Savings Plan to assess the scale of director exposure.
- Confirm the specific ownership percentages of Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J S Heslop within the respective trusts.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions for the transferred shares.